https://scholars.lib.ntu.edu.tw/handle/123456789/487382
標題: | Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma | 作者: | CHIH-HUNG HSU Chen J. Wu C.-Y. ANN-LII CHENG YEONG-SHIAU PU |
公開日期: | 2001 | 卷: | 21 | 期: | 1 B | 起(迄)頁: | 711-715 | 來源出版物: | Anticancer Research | 摘要: | Background: We have previously demonstrated that tamoxifen enhanced the chemosensitivity of bladder cancer cells in vitro. In this pilot study, we tested the modulating effect of high-dose tamoxifen to conventional cisplatin, methotrexate, and vinblastine combination chemotherapy (CMV-T) for transitional cell carcinoma (TCC). Patients and Methods: Between Nov. 1994 and Mar. 1999, 30 TCC patients were enrolled. Nine patients had muscle-invasive bladder TCC; 21 patients had either unresectable locally advanced diseases or distant metastases. CMV-T consisted of cisplatin 50 mg/m2/day, day 1 & 2; methotrexate 30 mg/m2/day, day 1 & 8; vinblastine 3 mg/m2/day, day 1 & 8; and tamoxifen 200 mg/m2/day, days 1 through 4. Results: A total of 98 courses had been given with an average of 3.27 courses per patient (range: 1-7). Grade III/IV leukopenia and thrombocytopenia occurred in 18% and 21% of total courses, respectively. There were 7 episodes of neutropenic fever, and 3 patients died of sepsis. Non-haematologic toxicities were generally mild. There was no venous thrombosis. Out of 26 patients eligible for evaluation of response, 1 complete and 14 partial responses with an overall response rate of 58% (95% confidence interval: 38-75%) were observed. The mean survival of all patients was 8 months. Conclusions: The toxicity of CMV-T chemotherapy is moderate, but generally manageable. The response rate of CMV-T for patients with advanced TCC seems to be only comparable to most conventional cisplatin-based combinations. The possible benefit of tamoxifen to enhance chemosensitivity of TCC needs further investigation. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035062381&partnerID=40&md5=21f32e7ef7f7ab0cc05540511cb2f463 https://scholars.lib.ntu.edu.tw/handle/123456789/487382 |
ISSN: | 0250-7005 | SDG/關鍵字: | antineoplastic agent; cisplatin; methotrexate; tamoxifen; vinblastine; adult; aged; article; bladder carcinoma; bone marrow toxicity; cancer combination chemotherapy; cancer survival; clinical article; clinical trial; drug induced disease; drug megadose; female; gastrointestinal toxicity; human; male; priority journal; sepsis; transitional cell carcinoma; treatment outcome; urogenital tract tumor; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Methotrexate; Middle Aged; Neutropenia; Remission Induction; Sepsis; Tamoxifen; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。